These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28848322)

  • 1. Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.
    Lodhi SA; Reddy JL; Peram V
    Clin Ophthalmol; 2017; 11():1399-1406. PubMed ID: 28848322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.
    Zhang C; Wang Y; Chen Y; Zhou H; Hong Q; Yu X; Ng TK; Cen LP
    BMC Ophthalmol; 2023 May; 23(1):199. PubMed ID: 37147563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
    Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
    Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
    Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
    Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy.
    Minami K; Egawa M; Kajita K; Murao F; Mitamura Y
    Case Rep Ophthalmol; 2021; 12(3):952-960. PubMed ID: 35082654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.
    Rahman N; Artiaga JCM; Bouras K; Luis J; Rees A; Westcott M
    J Ophthalmic Inflamm Infect; 2023 May; 13(1):27. PubMed ID: 37204477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
    Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
    BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada Disease: A Case Series in a Tertiary Eye Center.
    Shrestha P; Sharma S; Kharel R
    Case Rep Ophthalmol Med; 2021; 2021():8848659. PubMed ID: 33552608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior segment recurrences in Vogt-Koyanagi-Harada disease.
    Sachdev N; Gupta V; Gupta A; Singh R
    Int Ophthalmol; 2008 Oct; 28(5):339-45. PubMed ID: 17898934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report.
    Koyama M; Nishijima E; Honda T; Gonmori-Ohta C; Sasamoto T; Tanaka K; Watanabe A; Nakano T; Akiyama M
    BMC Ophthalmol; 2024 Mar; 24(1):115. PubMed ID: 38481205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia.
    Hasan AN; Mustapha M; Wan HAHW
    Cesk Slov Oftalmol; 2024; 80(3):140-144. PubMed ID: 38413229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Band-shaped keratopathy in Chinese patients with Vogt-Koyanagi-Harada syndrome.
    Yang P; Sun M
    Cornea; 2011 Dec; 30(12):1336-40. PubMed ID: 21934492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
    Nakayama M; Keino H; Watanabe T; Okada AA
    Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
    Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
    Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior subtenon triamcinolone acetonide injection as a primary treatment in eyes with acute Vogt-Koyanagi-Harada disease.
    Hosoda Y; Hayashi H; Kuriyama S
    Br J Ophthalmol; 2015 Sep; 99(9):1211-4. PubMed ID: 25792626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt Koyanagi Harada Disease In Paediatric Age Group: Clinical Characteristics, Remission, Recurrences and Complications in Asian Indian Population.
    Kaza H; Tyagi M; Agarwal K; Behera S; Pappuru RR; Mohan S; Saldanha M; Videkar C; Basu S; Pathengay A; Murthy S
    Semin Ophthalmol; 2022 Feb; 37(2):187-192. PubMed ID: 34224303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
    Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
    Concha-Del Río LE; Gómez L; Arellanes-García L
    Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spectrum of Vogt-Koyanagi-Harada disease in South India.
    Murthy SI; Moreker MR; Sangwan VS; Khanna RC; Tejwani S
    Int Ophthalmol; 2007; 27(2-3):131-6. PubMed ID: 17318321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.
    Khairallah M; Zaouali S; Messaoud R; Chaabane S; Attia S; Ben Yahia S; Hmidi K
    Int Ophthalmol; 2007; 27(2-3):125-30. PubMed ID: 17203358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.